Literature DB >> 24997132

Fibrolamellar hepatocellular carcinoma mimicking ornithine transcarbamylase deficiency.

Raashda A Sulaiman1, Tarekegn Geberhiwot.   

Abstract

We report an unusual case of recurrent non-hepatic hyperammonaemic encephalopathy in an adult patient. She had a previous history of treated fibrolamellar hepatocellular carcinoma (FLC). This posed a diagnostic challenge, as she had normal liver function tests and normal looking liver on imaging but with extra hepatic metastases. This case highlights the importance of measuring plasma ammonia levels in all patients presenting with unexplained acute confusion. Clinical awareness of non-hepatic hyperammonaemic encephalopathy can contribute to early diagnosis and timely initiation of life-saving treatment. Delay in treatment results in irreversible brain damage, deep coma and death. Treatment of hyperammonaemia must begin prior to confirmation of aetiology, for a favourable outcome. This case also highlights the need for further research to understand the exact mechanism of hyperammonaemia in hepatocellular carcinoma.

Entities:  

Year:  2014        PMID: 24997132      PMCID: PMC4221297          DOI: 10.1007/8904_2014_318

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  5 in total

1.  Hepatic encephalopathy and orotic aciduria associated with hepatocellular carcinoma in a noncirrhotic liver.

Authors:  L J Jeffers; R A Dubow; L Zieve; K R Reddy; A S Livingstone; S Neimark; M Viamonte; E R Schiff
Journal:  Hepatology       Date:  1988 Jan-Feb       Impact factor: 17.425

2.  Imbalance in ornithine metabolism in hepatomas of different growth rates as expressed in behavior of L-ornithine carbamyl transferase activity.

Authors:  G Weber; S F Queener; H P Morris
Journal:  Cancer Res       Date:  1972-09       Impact factor: 12.701

3.  Hyperammonemia after chemotherapy in an adolescent with hepatocellular carcinoma.

Authors:  S S Winter; E Rose; R Katz
Journal:  J Pediatr Gastroenterol Nutr       Date:  1997-11       Impact factor: 2.839

4.  Hyperammonemic encephalopathy: a rare presentation of fibrolamellar hepatocellular carcinoma.

Authors:  Saurabh Sethi; Nishant Tageja; Jatinder Singh; Haitham Arabi; Maneesh Dave; Apurva Badheka; Sanjay Revankar
Journal:  Am J Med Sci       Date:  2009-12       Impact factor: 2.378

5.  Postchemotherapy hyperammonemic encephalopathy emulating ornithine transcarbamoylase (OTC) deficiency.

Authors:  Joseph S Chan; Cary O Harding; Charles D Blanke
Journal:  South Med J       Date:  2008-05       Impact factor: 0.954

  5 in total
  7 in total

1.  Hyperammonemic encephalopathy in a patient with fibrolamellar hepatocellular carcinoma: case report and literature review.

Authors:  Janice Cho; Joy C Y Chen; Jonas Paludo; Erin E Conboy; Brendan C Lanpher; Steven R Alberts; Thorvardur R Halfdanarson
Journal:  J Gastrointest Oncol       Date:  2019-06

Review 2.  Clinical and biochemical footprints of inherited metabolic diseases. VIII. Neoplasias.

Authors:  Teodoro Jerves; Nenad Blau; Carlos R Ferreira
Journal:  Mol Genet Metab       Date:  2022-03-28       Impact factor: 4.204

3.  Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm.

Authors:  Claudia I Chapuy; Inderneel Sahai; Rohit Sharma; Andrew X Zhu; Olga N Kozyreva
Journal:  Oncologist       Date:  2016-03-14

4.  A Proposed Physiopathological Pathway to Hyperammonemic Encephalopathy in a Non-Cirrhotic Patient with Fibrolamellar Hepatocellular Carcinoma without Ornithine Transcarbamylase (OTC) Mutation.

Authors:  Rodrigo C Surjan; Elizabeth S Dos Santos; Tiago Basseres; Fabio F Makdissi; Marcel A Machado
Journal:  Am J Case Rep       Date:  2017-03-08

5.  Hyperammonemic encephalopathy: An unusual presentation of fibrolamellar hepatocellular carcinoma.

Authors:  Nimish Thakral; Douglas A Simonetto
Journal:  Clin Mol Hepatol       Date:  2019-08-16

6.  Clinical features and surgical outcomes of fibrolamellar hepatocellular carcinoma: retrospective analysis of a single-center experience.

Authors:  Anastasia Lemekhova; Daniel Hornuss; Georgios Polychronidis; Philipp Mayer; Christian Rupp; Thomas Longerich; Karl-Heinz Weiss; Markus Büchler; Arianeb Mehrabi; Katrin Hoffmann
Journal:  World J Surg Oncol       Date:  2020-05-12       Impact factor: 2.754

7.  Fibrolamellar hepatocellular carcinoma-related hyperammonemic encephalopathy: Up to now and next steps.

Authors:  Rodrigo Cañada Trofo Surjan; Elizabeth Santana Dos Santos; Sergio do Prado Silveira; Fabio Ferrari Makdissi; Marcel Autran Cesar Machado
Journal:  Clin Mol Hepatol       Date:  2019-11-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.